Douglas Lane & Associates, LLC Amgen Inc Transaction History

Douglas Lane & Associates, LLC

$6.79 Billion
Q1 2024

A detailed history of Douglas Lane & Associates, LLC transactions in Amgen Inc stock. As of the latest transaction made, Douglas Lane & Associates, LLC holds 14,745 shares of AMGN stock, worth $4.58 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

14,745

Previous 14,795 0.34%

Holding current value

$4.58 Million

Previous $4.26 Million 1.62%

% of portfolio

0.06%

Previous 0.07%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 11, 2024	SELL	$268.87 - $324.56 $13,443 - $16,228	-50 Reduced 0.34%	14,745 $4.19 Million
Q4 2023 Jan 17, 2024	SELL	$255.7 - $288.46 $122,736 - $138,460	-480 Reduced 3.14%	14,795 $4.26 Million
Q3 2023 Oct 16, 2023	BUY	$218.65 - $271.46 $83,961 - $104,240	384 Added 2.58%	15,275 $4.11 Million
Q2 2023 Jul 19, 2023	SELL	$214.27 - $253.37 $19,498 - $23,056	-91 Reduced 0.61%	14,891 $3.31 Million
Q1 2023 Apr 17, 2023	SELL	$225.79 - $275.2 $64,801 - $78,982	-287 Reduced 1.88%	14,982 $3.62 Million

Q4 2022 Feb 14, 2023	SELL	$229.03 - $291.01 $18,780 - $23,862	-82 Reduced 0.53%	15,269 $4.01 Million
Q4 2022 Jan 17, 2023	SELL	$229.03 - $291.01 $233,152 - $296,248	-1,018 Reduced 6.22%	15,351 $4.03 Million
Q3 2022 Oct 14, 2022	SELL	$224.46 - $253.15 $81,254 - $91,640	-362 Reduced 2.16%	16,369 $3.69 Million
Q2 2022 Jul 18, 2022	SELL	$230.71 - $256.74 $523,019 - $582,029	-2,267 Reduced 11.93%	16,731 $4.07 Million
Q1 2022 Apr 25, 2022	SELL	$219.27 - $242.57 $740,255 - $818,916	-3,376 Reduced 15.09%	18,998 $4.59 Million
Q4 2021 Jan 25, 2022	SELL	$198.88 - $227.6 $193,908 - $221,910	-975 Reduced 4.18%	22,374 $5.03 Million
Q3 2021 Oct 21, 2021	SELL	$212.27 - $248.7 $706,859 - $828,171	-3,330 Reduced 12.48%	23,349 $4.97 Million
Q2 2021 Jul 19, 2021	SELL	$233.58 - $259.14 $1.2 Million - $1.33 Million	-5,130 Reduced 16.13%	26,679 $6.5 Million
Q1 2021 Apr 19, 2021	SELL	$221.91 - $258.6 $898,735 - $1.05 Million	-4,050 Reduced 11.29%	31,809 $7.91 Million
Q4 2020 Jan 14, 2021	SELL	$216.38 - $257.67 $817,916 - $973,992	-3,780 Reduced 9.54%	35,859 $8.25 Million
Q3 2020 Oct 19, 2020	SELL	$234.65 - $260.95 $1.08 Million - $1.21 Million	-4,618 Reduced 10.43%	39,639 $10.1 Million
Q2 2020 Jul 28, 2020	SELL	$197.81 - $242.74 $626,068 - $768,272	-3,165 Reduced 6.67%	44,257 $10.4 Million
Q1 2020 Apr 20, 2020	SELL	$182.24 - $241.7 $364,844 - $483,883	-2,002 Reduced 4.05%	47,422 $9.61 Million
Q4 2019 Jan 27, 2020	SELL	$189.21 - $243.2 $438,588 - $563,737	-2,318 Reduced 4.48%	49,424 $11.9 Million
Q3 2019 Oct 16, 2019	SELL	$174.11 - $208.62 $1.81 Million - $2.17 Million	-10,389 Reduced 16.72%	51,742 $10 Million
Q2 2019 Jul 08, 2019	SELL	$166.7 - $195.41 $2.39 Million - $2.8 Million	-14,319 Reduced 18.73%	62,131 $11.4 Million
Q1 2019 Apr 23, 2019	SELL	$180.87 - $203.88 $1.39 Million - $1.57 Million	-7,695 Reduced 9.14%	76,450 $14.5 Million
Q4 2018 Jan 17, 2019	SELL	$178.4 - $208.25 $1.07 Million - $1.25 Million	-6,020 Reduced 6.68%	84,145 $16.4 Million
Q3 2018 Oct 09, 2018	SELL	$185.29 - $208.89 $827,505 - $932,902	-4,466 Reduced 4.72%	90,165 $18.7 Million
Q2 2018 Jul 23, 2018	SELL	$166.05 - $186.51 $3.6 Million - $4.05 Million	-21,699 Reduced 18.65%	94,631 $17.5 Million
Q1 2018 Apr 23, 2018	SELL	$169.43 - $198.0 $3.51 Million - $4.1 Million	-20,699 Reduced 15.11%	116,330 $19.8 Million
Q4 2017 Jan 24, 2018	SELL	$168.79 - $188.59 $3.64 Million - $4.07 Million	-21,578 Reduced 13.6%	137,029 $23.8 Million
Q3 2017 Oct 19, 2017	BUY	$167.29 - $191.0 $26.5 Million - $30.3 Million	158,607	158,607 $29.6 Million

Others Institutions Holding AMGN

# of Institutions

2,932

Shares Held

401M

Call Options Held

6.59M

Put Options Held

6.6M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $166B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Douglas Lane & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Douglas Lane & Associates, LLC with notifications on news.

Account

Douglas Lane & Associates, LLC Amgen Inc Transaction History